Terumo acquires OrganOx to enter Organ transplant market

Terumo Corporation announced that it has a definitive agreement with OrganOx Limited and its shareholders. This agreement, dated August 23, 2025, is for the acquisition of all outstanding shares of OrganOx. After the transaction, OrganOx will be a fully owned subsidiary of Terumo. The total transaction value is about USD $1.5 billion.

OrganOx, founded in 2008 by Professors Peter Friend and Constantin Coussios, started as a spin-off from the University of Oxford. It leads in advanced organ preservation technology. The company focuses on Normothermic Machine Perfusion (NMP) devices. These devices help preserve organs longer by circulating oxygen and nutrient-rich fluid at near-body temperature. These devices do more than just preserve organs. They let us monitor the organ’s condition in real-time during storage and transport. This helps lower the chances of transplanting organs that aren’t working well. The technology boosts transplant success rates. It also makes better use of organs from marginal donors.

こちらもお読みください： Deerhold launches platform for healthcare decision support

This acquisition marks Terumo’s strategic move into organ transplantation. This sector has significant unmet medical needs and strong growth potential. Terumo Corporation  plans to combine its years of experience in medical device design with OrganOx’s NMP expertise. This partnership aims to create innovative organ preservation solutions for people around the world. Terumo wants to help more patients waiting for transplants. They aim to improve transplant medicine and tackle key challenges. This includes better organ use, allowing marginal donor organs, boosting post-transplant results, and easing the load on healthcare workers by reducing nighttime and emergency procedures.